Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings

MONDAY, Aug. 17, 2026-- Nearly 1 in 4 patients treated with lecanemab for mild cognitive impairment or mild Alzheimer disease (AD) with confirmed amyloid pathology develop amyloid-related imaging abnormality (ARIA), according to a study published...